Impaired tumor death receptor signaling drives resistance to CAR T cell therapy
N. Singh, O. Shestova, P. Ravikumar, K. Hayer, S. J. Hong, E. J. Orlando, K. T. Mueller, C. R. Good, S. L. Berger, O. Shalem, M. D. Weitzman, S. A. Grupp, C. H. June, S. Gill, M. Ruella
This study identifies impaired death receptor signaling as a driver of resistance to CAR T cell therapy in B-cell leukemia by showing its role in tumor survival and T cell dysfunction.
bioRxiv · May 5, 2019 · PreprintImmunology